Performance of In Silico Prediction Tools for the Detection of Germline Copy Number Variations in Cancer Predisposition Genes in 4208 Female Index Patients with Familial Breast and Ovarian Cancer.

CNV HBOC breast/ovarian cancer susceptibility genes multigene panel sequencing

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
01 Jan 2021
Historique:
received: 20 11 2020
revised: 17 12 2020
accepted: 22 12 2020
entrez: 6 1 2021
pubmed: 7 1 2021
medline: 7 1 2021
Statut: epublish

Résumé

The identification of germline copy number variants (CNVs) by targeted next-generation sequencing (NGS) frequently relies on in silico CNV prediction tools with unknown sensitivities. We investigated the performances of four in silico CNV prediction tools, including one commercial (Sophia Genetics DDM) and three non-commercial tools (ExomeDepth, GATK gCNV, panelcn.MOPS) in 17 cancer predisposition genes in 4208 female index patients with familial breast and/or ovarian cancer (BC/OC). CNV predictions were verified via multiplex ligation-dependent probe amplification. We identified 77 CNVs in 76 out of 4208 patients (1.81%); 33 CNVs were identified in genes other than

Identifiants

pubmed: 33401422
pii: cancers13010118
doi: 10.3390/cancers13010118
pmc: PMC7794674
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Koeln Fortune Program, Faculty of Medicine, University of Cologne, Germany
ID : grant number not applicable

Références

Cancer. 2012 Nov 1;118(21):5210-6
pubmed: 22544547
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Mutat Res. 2019 Jan - Mar;779:114-125
pubmed: 31097148
Nucleic Acids Res. 2002 Jun 15;30(12):e57
pubmed: 12060695
Nucleic Acids Res. 2015 Mar 31;43(6):e39
pubmed: 25618849
Eur J Hum Genet. 2020 Dec;28(12):1645-1655
pubmed: 32561899
Sci Rep. 2015 May 21;5:10424
pubmed: 25994375
Nat Genet. 2016 Oct;48(10):1107-11
pubmed: 27533299
J Mol Diagn. 2017 Nov;19(6):809-816
pubmed: 28822785
Genome Biol. 2018 Nov 26;19(1):202
pubmed: 30477554
Breast Cancer Res. 2013 Dec 20;15(6):R120
pubmed: 24359560
Mol Diagn Ther. 2017 Jun;21(3):303-313
pubmed: 28290094
Bioinformatics. 2012 Nov 1;28(21):2747-54
pubmed: 22942019
Genome Res. 2017 May;27(5):677-685
pubmed: 27895111
J Med Genet. 2018 Feb;55(2):114-121
pubmed: 29074561
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
J Mol Diagn. 2017 Nov;19(6):905-920
pubmed: 28818680
Clin Genet. 2004 Dec;66(6):488-95
pubmed: 15521975
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Genet Mol Biol. 2009 Jul;32(3):437-46
pubmed: 21637503
Hum Mutat. 2017 Jul;38(7):889-897
pubmed: 28449315
Expert Rev Mol Diagn. 2019 Sep;19(9):795-802
pubmed: 31429350
Nat Rev Genet. 2011 May;12(5):363-76
pubmed: 21358748
J Natl Cancer Inst. 2020 Dec 14;112(12):1242-1250
pubmed: 32107557
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Breast Cancer Res Treat. 2007 Mar;102(1):119-22
pubmed: 16897426
Breast Cancer Res Treat. 2016 Oct;159(3):585-90
pubmed: 27581129
Clin Chim Acta. 2018 May;480:173-179
pubmed: 29458049
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Genome Med. 2016 Aug 08;8(1):82
pubmed: 27503473
J Med Genet. 2016 Jul;53(7):465-71
pubmed: 26928436

Auteurs

Louisa Lepkes (L)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Mohamad Kayali (M)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Britta Blümcke (B)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Jonas Weber (J)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Malwina Suszynska (M)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Sandra Schmidt (S)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Julika Borde (J)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Katarzyna Klonowska (K)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Barbara Wappenschmidt (B)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Jan Hauke (J)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Piotr Kozlowski (P)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Rita K Schmutzler (RK)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Eric Hahnen (E)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Corinna Ernst (C)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, 50931 Cologne, Germany.

Classifications MeSH